Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities

Table 1 Ongoing studies with Metmb (onartuzumab)

NCT Number	Combination Drugs	PHASES	URL
NCT01897038	Drug: Onartuzumab	Phase1	https://ClinicalTrials.gov/show/NCT01897038
NCT01897038	Drug: Sorafenib	Phase1	https://ClinicalTrials.gov/show/NCT01897038
NCT01519804	Drug: Placebo	Phase2	https://ClinicalTrials.gov/show/NCT01519804
	Drug: cisplatin/carboplatin
	Drug: onartuzumab
	Drug: paclitaxel
NCT00854308	Drug: Erlotinib HCl	Phase2	https://ClinicalTrials.gov/show/NCT00854308
	Drug: MetMAb
	Drug: placebo (0.9% saline)
NCT01496742	Drug: Placebo	Phase2	https://ClinicalTrials.gov/show/NCT01496742
	Drug: RO5490258
	Drug: bevacizumab [Avastin]
	Drug: cisplatin/carboplatin
	Drug: paclitaxel
	Drug: pemetrexed
NCT02031744	Drug: erlotinib [Tarceva]	Phase3	https://ClinicalTrials.gov/show/NCT02031744
	Drug: Placebo
	Drug: Onartuzumab [MetMAb]
NCT01887886	Drug: erlotinib	Phase3	https://ClinicalTrials.gov/show/NCT01887886
	Drug: onartuzumab
	Drug: placebo
NCT01456325	Drug: Erlotinib	Phase 3	https://ClinicalTrials.gov/show/NCT01456325
	Drug: Onartuzumab (MetMab)
	Drug: Placebo

ISSN: 1476-4598